Registered title, quoted from ClinicalTrials.gov
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06471205, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Subjects with histologically and/or cytologically confirmed, inoperable locally advanced or recurrent or metastatic triple-negative breast cancer;
Inclusion criterion 5
Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;
Inclusion criterion 10
6 months prior to screening needs treatment intervention unstable thrombotic events;
Exclusion criterion 13
ECOG 0 or 1;
Inclusion criterion 4
No blood transfusion, no use of cell growth factors and/or platelet raising drugs within 14 days before screening, and the organ function level must meet the requirements;
Inclusion criterion 9
Must have at least one place in accordance with RECIST v1.1 define measurable lesions;
Inclusion criterion 8
Other malignant tumors that progressed or required treatment within 5 years before the first dose;
Exclusion criterion 9
HIV antibody positive, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
Exclusion criterion 18
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06471205, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntarily sign the informed consent and follow the requirements of the protocol;
- Age: ≥18 years old and ≤75 years old;
- Expected survival time ≥3 months;
- ECOG 0 or 1;
- Subjects with histologically and/or cytologically confirmed, inoperable locally advanced or recurrent or metastatic triple-negative breast cancer;
- Patients should not have received previous systemic therapy for unresectable, locally advanced, recurrent, or metastatic triple-negative breast cancer;
- A archived tumor tissue specimen or fresh tissue specimen of the primary or metastatic lesion within 2 years must be provided;
- Must have at least one place in accordance with RECIST v1.1 define measurable lesions;
- No blood transfusion, no use of cell growth factors and/or platelet raising drugs within 14 days before screening, and the organ function level must meet the requirements;
- Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;
- For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, the serum or urine pregnancy test must be negative, and the patient must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.
Exclusion Criteria:
- ADC drugs that have received topoisomerase I inhibitors as small molecule toxins;
- Palliative radiotherapy within 2 weeks before the first dose;
- Patients with checkpoint inhibitors prior to neoadjuvant/adjuvant chemotherapy;
- Use of an immunomodulatory drug within 14 days before the first dose of study drug;
- The history of severe cardiovascular and cerebrovascular diseases in the past six months was screened;
- QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
- Active autoimmune and inflammatory diseases;
- Receiving long-term systemic corticosteroid therapy, etc., before the first dose;
- Other malignant tumors that progressed or required treatment within 5 years before the first dose;
- Presence of: a) poorly controlled diabetes mellitus before starting study treatment; b) severe complications associated with diabetes mellitus; c) a glycated hemoglobin level of 8% or more; d) hypertension poorly controlled by two antihypertensive drugs; e) history of hypertensive crisis or hypertensive encephalopathy;
- Present grade ≥2 radiation pneumonitis according to the RTOG/EORTC definition; Patients with current ILD;
- Complicated with pulmonary diseases leading to clinically severe respiratory impairment;
- 6 months prior to screening needs treatment intervention unstable thrombotic events;
- Patients with active central nervous system metastases;
- Patients with massive or symptomatic effusions or poorly controlled effusions;
- Allergic history to recombinant humanized antibody or human-mouse chimeric antibody or allergic to any excipients of the test drug;
- Prior organ transplantation or allogeneic hematopoietic stem cell transplantation;
- HIV antibody positive, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
- Serious infection within 4 weeks before the first dose of study drug; Signs of pulmonary infection or active pulmonary inflammation within 4 weeks;
- Participated in another clinical trial within 4 weeks before the first dose;
- Patients with superior vena cava syndrome should not be rehydrated;
- Have a history of psychotropic substance abuse with an inability to quit or a history of severe neurological or psychiatric illness;
- Imaging examination showed that the tumor had invaded or wrapped the large thoracic vessels;
- Serious unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;
- Clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
- Subjects who are scheduled to receive live vaccine or receive live vaccine within 28 days before the first dose;
- Other circumstances considered by the investigator to be inappropriate for participation in the trial.
Quoted from ClinicalTrials.gov, NCT06471205, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06471205, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.